Search Results
Sara M. Tolaney, MD, MPH discusses the TAILORx study
Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”
SABCS22: Sara Tolaney, MD, MPH | Dana-Farber Cancer Institute
RxPONDER: sparing chemotherapy in node-positive early-stage breast cancer
ESMO22: Breast cancer research by Sara Tolaney, MD | Dana-Farber Cancer Institute
Dr. Toomey Discusses Findings of TAILORx Trial
Sara M. Tolaney, MD, MPH, shares outcomes from the MONALEESA-7 trial
Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably
Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer
Is chemo necessary? TAILORx Analysis
Dr Richard De Boer discusses the TAILORx trial of OncotypeDX
Where are we in sequencing ADCs in HR+ breast cancer?
